tetano
Editor, Senior Moderator
Nanomedicine. 2016 Sep 10. pii: S1549-9634(16)30151-4. doi: 10.1016/j.nano.2016.09.001. [Epub ahead of print]
[h=1]Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.[/h] Wang L[SUP]1[/SUP], Chang TZ[SUP]2[/SUP], He Y[SUP]3[/SUP], Kim JR[SUP]4[/SUP], Wang S[SUP]5[/SUP], Mohan T[SUP]6[/SUP], Berman Z[SUP]7[/SUP], Tompkins SM[SUP]8[/SUP], Tripp RA[SUP]9[/SUP], Compans RW[SUP]10[/SUP], Champion JA[SUP]11[/SUP], Wang BZ[SUP]12[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Recurring influenza viruses pose an annual threat to public health. A time-saving, cost-effective and egg-independent influenza vaccine approach is important particularly when responding to an emerging pandemic. We fabricated coated, two-layer protein nanoclusters from recombinant trimeric hemagglutinin from an avian-origin H7N9 influenza A virus as an approach for vaccine development in response to an emerging pandemic. Assessment of the virus-specific immune responses and protective efficacy in mice immunized with the nanoclusters demonstrated that the vaccine candidates were highly immunogenic, able to induce protective immunity and long-lasting humoral antibody responses to this virus without the use of adjuvants. Because the advantages of the highly immunogenic coated nanoclusters also include rapid productions in an egg-independent system, this approach has great potential for influenza vaccine production not only in response to an emerging pandemic, but also as a replacement for conventional seasonal influenza vaccines.
Copyright ? 2016. Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Influenza vaccine; pandemic influenza; protein nanoclusters
PMID: 27622321 DOI: 10.1016/j.nano.2016.09.001
[PubMed - as supplied by publisher]
[h=1]Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.[/h] Wang L[SUP]1[/SUP], Chang TZ[SUP]2[/SUP], He Y[SUP]3[/SUP], Kim JR[SUP]4[/SUP], Wang S[SUP]5[/SUP], Mohan T[SUP]6[/SUP], Berman Z[SUP]7[/SUP], Tompkins SM[SUP]8[/SUP], Tripp RA[SUP]9[/SUP], Compans RW[SUP]10[/SUP], Champion JA[SUP]11[/SUP], Wang BZ[SUP]12[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Recurring influenza viruses pose an annual threat to public health. A time-saving, cost-effective and egg-independent influenza vaccine approach is important particularly when responding to an emerging pandemic. We fabricated coated, two-layer protein nanoclusters from recombinant trimeric hemagglutinin from an avian-origin H7N9 influenza A virus as an approach for vaccine development in response to an emerging pandemic. Assessment of the virus-specific immune responses and protective efficacy in mice immunized with the nanoclusters demonstrated that the vaccine candidates were highly immunogenic, able to induce protective immunity and long-lasting humoral antibody responses to this virus without the use of adjuvants. Because the advantages of the highly immunogenic coated nanoclusters also include rapid productions in an egg-independent system, this approach has great potential for influenza vaccine production not only in response to an emerging pandemic, but also as a replacement for conventional seasonal influenza vaccines.
Copyright ? 2016. Published by Elsevier Inc.
[h=4]KEYWORDS:[/h] Influenza vaccine; pandemic influenza; protein nanoclusters
PMID: 27622321 DOI: 10.1016/j.nano.2016.09.001
[PubMed - as supplied by publisher]